Anvisa (the National Health Surveillance Agency) has announced the resumption of the publication of medical device price monitoring data in its Business Intelligence (BI) panels. The activity, which had been temporarily suspended, is now back, with improvements to the process and guarantees of greater efficiency and precision.
Reasons for the Temporary Suspension
The temporary suspension of data disclosure was due to changes in Anvisa’s Internal Regulations, which resulted in the transfer of responsibility for the activity to the Executive Secretariat of the Medicines Market Regulation Chamber (SCMED). During this period, the data underwent a review to ensure a more efficient and accurate experience for users, improving transparency and the quality of information.
The Return of Disclosure
With the completion of the review and improvement of the process, Anvisa updated its price panels and made them accessible to the public again. Now, users can closely monitor the evolution of medical device prices on the market, a valuable tool for healthcare professionals, companies and other interested parties.
Importance of Price Monitoring
Price monitoring of medical devices is essential to promote transparency in the market and provide relevant information for regulatory and sectoral analysis. This measure also allows for more detailed monitoring of price fluctuations, which can directly impact purchasing decisions and public health policies.
Commitment to Transparency and Access to Information
The resumption of data disclosure reinforces Anvisa’s commitment to making clear and accessible information available to society, promoting an environment of greater transparency in the medical devices sector and ensuring that everyone involved has access to up-to-date data.
Access to Price Panels
The price monitoring panels are now available and can be accessed directly on the Anvisa website. Click here to access the information.
With the resumption of data disclosure, Anvisa reaffirms its responsibility to promote transparency and access to information on the medical devices market. The review and improvement of the process guarantees an even more effective tool for monitoring price fluctuations, helping with decision-making and strategic planning in the sector.
